Boundless Bio, Inc.(US:BOLD)2025-11-05 12:05Financial Performance - Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025, down from $152.1 million at the end of 2024[14] - Net loss for Q3 2025 was $13.9 million, an improvement from a net loss of $16.5 million in Q3 2024[9] - The accumulated deficit increased to $246.8 million as of September 30, 2025, compared to $201.5 million at the end of 2024[14] - Total operating expenses for Q3 2025 were $15.1 million, down from $18.7 million in Q3 2024[13] Research and Development - Research and Development (R&D) expenses were $10.7 million for Q3 2025, a decrease of 24% compared to $14.1 million for the same period in 2024[9] - The company expects to submit an investigational new drug (IND) application for BBI-940 and initiate a first-in-human Phase 1 clinical trial in the first half of 2026[5] - Enrollment is ongoing in the BBI-355/BBI-825 combination arm of the POTENTIATE trial, with initial proof-of-concept clinical data expected within the existing cash runway timeline[3] - The company is developing BBI-940, a potentially first-in-class, orally bioavailable, selective Kinesin degrader targeting ecDNA segregation and inheritance[4] General and Administrative Expenses - General and Administrative (G&A) expenses were $4.5 million for Q3 2025, slightly down from $4.6 million in Q3 2024[9] Cash Position - The company has $118 million in cash to support operations into the first half of 2028[1]